N. Yasarawan et al. / Journal of Molecular Structure 1031 (2013) 144–151
151
4.5. Preliminary study on the insulin-mimetic effect of the complex
[9] M. Yamaguchi, K. Wakasugi, R. Saito, Y. Adachi, Y. Yoshikawa, H. Sakurai, A.
Katoh, J. Inorg. Biochem. 100 (2006) 260–269.
[
10] Y. Yoshikawa, E. Ueda, H. Miyake, H. Sakurai, Y. Kojima, Biochem. Biophys. Res.
Commun. 281 (2001) 1190–1193.
Diabetes in laboratory rats was induced by means of
intraperitoneal injection (IP) of streptozotocin. The solution of
chromium(III) complex with 1-hydroxy-2-pyridinone-6-carboxylic
acid was injected to a group of diabetic rats whereas the
other reference chromium(III) compounds, namely chromium(III)
chloride and chromium(III) picolinate were used for the other
groups. The diabetic rats in the control group received 0.9% normal
saline. At different periods after injection, the blood samples
were withdrawn from the rats and the glucose levels in plasma
analyzed. It was found that injection of the chromium(III) complex
with 1-hydroxy-2-pyridinone-6-carboxylic acid to diabetic rats
was able to lower the plasma glucose levels by 40% in 5 h (see
Supplementary Material for more information on this preliminary
study).
[11] Y. Yoshikawa, E. Ueda, K. Kawabe, H. Miyake, T. Takino, H. Sakurai, Y. Kojima, J.
Biol. Inorg. Chem. 7 (2002) 68–73.
[
[
12] C.M. Davis, J.B. Vincent, Biochemistry 36 (1997) 4382–4385.
13] H. Wang, A. Kruszewski, D.L. Brautigan, Biochemistry 44 (2005) 8167–8175.
[14] G.W. Evans, U.S. Patent 4,315,927.
[
[
15] D.D.D. Hepburn, J.B. Vincent, J. Inorg. Biochem. 94 (2003) 86–93.
16] M.M. Bailey, J.G. Boohaker, R.D. Sawyer, J.E. Behling, J.F. Rasco, J.J. Jernigan, R.D.
Hood, J.B. Vincent, Birth Defects Res. Part B 77 (2006) 244–249.
[17] J.K. Speetjens, R.A. Collins, J.B. Vincent, S.A. Woski, Chem. Res. Toxicol. 12
1999) 483–487.
18] X. Yang, S.Y. Li, F. Dong, J. Ren, N. Sreejayan, J. Inorg. Biochem. 100 (2006)
187–1193.
(
[
1
[19] P. Zhao, J. Wang, H. Ma, Y. Xiao, L. He, C. Tong, Z. Wang, Q. Zheng, E.K. Dolence,
S. Nair, J. Ren, J. Li, Biochem. Pharmacol. 77 (2009) 1002–1010.
[
20] M.R. Kandadi, M.K. Unnikrishnan, A.K.S. Warrier, M. Du, J. Ren, N. Sreejayan, J.
Inorg. Biochem. 105 (2011) 58–62.
[21] F. Dong, M.R. Kandadi, J. Ren, N. Sreejayan, J. Nutr. 138 (2008) 1846–1851.
[
[
[
[
[
[
22] Y. Adachi, J. Yoshida, Y. Kodera, A. Kato, Y. Yoshikawa, Y. Kojima, H. Sakurai,
Biofactors 29 (2007) 213–223.
23] G.R. Willsky, A.B. Goldfine, P.J. Kostyniak, J.H. McNeill, L.Q. Yang, H.R. Khan,
D.C. Crans, J. Inorg. Biochem. 85 (2001) 33–42.
24] K.H. Thompson, J. Lichter, C. LeBel, M.C. Scaife, J.H. McNeill, C. Orvig, J. Inorg.
Biochem. 103 (2009) 554–558.
25] F. Li, X. Wu, T. Zhao, M. Zhang, J. Zhao, G. Mao, L. Yang, J. Trace Elem. Med. Biol.
25 (2011) 218–224.
5
. Conclusions
The synthesis routes of the chromium(III) complex with the
ligand 1,2-HOPO-6-carboxylic acid have been established. The
mass spectroscopic evidence and elemental analysis suggested
that the metal-to-ligand mole ratio of the complex was 1:3.
Consistent with the theoretical prediction, the experimental
spectroscopic data of the resulting complex indicated that the
ligand 1,2-HOPO-6-carboxylic acid chelated the chromium(III)
ion with its pyridinone carbonyl oxygen and N-oxide oxygen
atoms. By this pathway of chelation, the ligand functioned as a
bidentate chelating agent, forming the six-coordinate metal
complex with the stabilized five-membered chelate rings. In
addition, based on the preliminary results, the chromium
complex synthesized for the present study exhibited promising
insulin-mimetic property. To realize the therapeutic value of
the complex, the response of blood glucose levels to oral
administration as well as toxicity could be further investigated.
26] D. Margina, B. Velescu, V. Uivarosi, V. Aldea, S. Negres, N. Mitrea, Febs J. 277
(
2010) 61.
27] M. Badea, R. Olar, D. Marinescu, V. Uivarosi, V. Aldea, T.O. Nicolescu, J. Therm.
Anal. Calorim. 99 (2010) 823–827.
[28] J. Xu, D.G. Churchill, M. Botta, K.N. Raymond, Inorg. Chem. 43 (2004) 5492–
494.
[
5
29] W.C. Floyd, P.J. Klemm, D.E. Smiles, A.C. Kohlgruber, V.C. Pierre, J.L. Mynar,
J.M.J. Fréchet, K.N. Raymond, J. Am. Chem. Soc. 133 (2011) 2390–2393.
[30] A. Datta, K.N. Raymond, Acc. Chem. Res. 42 (2009) 938–947.
[
[
[
31] J.-M. Meyer, D. Hohnadel, F. Hallé, J. Gen. Microbiol. 135 (1989) 1479–1487.
32] H. Weizman, A. Shanzer, Chem. Commun. (2000) 2013–2014.
33] L.C. Uhlir, P.W. Durbin, N. Jeung, K.N. Raymond, J. Med. Chem. 36 (1993) 504–
509.
34] J. Xu, P.W. Durbin, B. Kullgren, S.N. Ebbe, L.C. Uhlir, K.N. Raymond, J. Med.
Chem. 45 (2002) 3963–3971.
35] F. Paquet, V. Chazel, P. Houpert, R. Guilmette, B. Muggenburg, Radiat. Prot.
Dosim. 105 (2003) 521–525.
36] P.W. Durbin, B. Kullgren, J. Xu, K.N. Raymond, Int. J. Radiat. Biol. 76 (2000)
[
[
[
[
[
[
1
99–214.
37] E.G. Moore, A. D’Aléo, J. Xu, K.N. Raymond, Aust. J. Chem. 62 (2009) 1300–
307.
38] M. Seitz, K. Do, A.J. Ingram, E.G. Moore, G. Muller, K.N. Raymond, Inorg. Chem.
8 (2009) 8469–8479.
Acknowledgments
1
This research was financially supported by the Thailand
Research Fund (Grant No. TRG478001) and the Faculty of
Science, Burapha University, Thailand. The authors thank National
Electronics and Computer Technology Center, Thailand for the
computing resources and Assoc. Prof. Sirintorn Yibchok-anun for
insulin-mimetic activity analysis.
4
39] A. D’Alé o, E.G. Moore, G. Szigethy, J. Xu, K.N. Raymond, Inorg. Chem. 48 (2009)
9316–9324.
[40] M. Nakai, F. Sekiguchi, M. Obata, C. Ohtsuki, Y. Adachi, H. Sakurai, C. Orvig, D.
Rehder, S. Yano, J. Inorg. Biochem. 99 (2005) 1275–1282.
[
[
[
41] K. Thipyapong, V. Ruangpornvisuti, J. Mol. Struct. 891 (2008) 1–10.
42] K.N. Raymond, R.C. Scarrow, D.L. White, U.S. Patent 4,698,431.
43] M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman,
J.A. Montgomery, T. Vreven, K.N. Kudin, J.C. Burant, J.M. Millam, S.S. Iyengar, J.
Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G.A. Petersson,
H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T.
Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J.E. Knox, H.P. Hratchian,
J.B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O.
Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, P.Y. Ayala, K.
Morokuma, G.A. Voth, P. Salvador, J.J. Dannenberg, V.G. Zakrzewski, S.
Dapprich, A.D. Daniels, M.C. Strain, O. Farkas, D.K. Malick, A.D. Rabuck, K.
Raghavachari, J.B. Foresman, J.V. Ortiz, Q. Cui, A.G. Baboul, S. Clifford, J.
Cioslowski, B.B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R.L.
Martin, D.J. Fox, T. Keith, M.A. Al-Laham, C.Y. Peng, A. Nanayakkara, M.
Challacombe, P.M.W. Gill, B. Johnson, W. Chen, M.W. Wong, C. Gonzalez, J.A.
Pople, Gaussian 03, Revision C.02, Gaussian Inc., Wallingford, CT, 2004.
44] A.D. Becke, J. Chem. Phys. 98 (1993) 5648–5652.
Appendix A. Supplementary material
References
[
[
[
[
1] J.B. Vincent, Polyhedron 20 (2001) 1–26.
2] R.A. Anderson, J. Am. Coll. Nutr. 17 (1998) 548–555.
3] R.A. Anderson, Diabetes Metab. 26 (2000) 22–27.
[
[
[
4] H. Sakurai, Y. Kojima, Y. Yoshikawa, K. Kawabe, H. Yasui, Coord. Chem. Rev. 226
45] C. Lee, W. Yang, R.G. Parr, Phys. Rev. B 37 (1988) 785–789.
46] N.M. O’Boyle, A.L. Tenderholt, K.M. Langner, J. Comput. Chem. 29 (2008) 839–
(
2002) 187–198.
5] H. Watanabe, M. Nakai, K. Komazawa, H. Sakurai, J. Med. Chem. 37 (1994) 876–
77.
[
845.
8
[
[
[
[
47] Y.-P. Tong, Inorg. Chim. Acta 362 (2009) 2167–2171.
[
[
[
6] H. Sakurai, Chem. Rec. 2 (2002) 237–248.
48] V. Barone, M. Cossi, J. Tomasi, J. Chem. Phys. 107 (1997) 3210–3221.
49] D.M. Stearns, W.H. Armstrong, Inorg. Chem. 31 (1992) 5178–5184.
50] W. Fürst, P. Gouzerh, Y. Jeannin, J. Coord. Chem. 8 (1979) 237–243.
7] H. Sakurai, Y. Adachi, Biometals 18 (2005) 319–323.
8] Y. Adachi, J. Yoshida, Y. Kodera, A. Kato, Y. Yoshikawa, Y. Kojima, H. Sakurai, J.
Biol. Inorg. Chem. 9 (2004) 885–893.